Revenue segments as reported by the company.

Medical Devices

Specialty Pharmaceuticals

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Royalty expense

Amortization expense

Intangible asset impairment charges

Contingent consideration net expense (benefit)

Restructuring net charges (credits)

Litigation-related net charges (credits)

Gain on disposal of businesses and assets

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Boston Scientific

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Boston Scientific reports solid Q4 performance and eyes global growth

Boston Scientific's Q4 performance was solid, with growth across regions and business units.
Challenges include potential sales growth hurdles in Q1 2023 and headwinds from tough comps and market adjustments.
Opportunities lie in continued momentum in key business units, successful product launches, and global growth prospects.
The company remains focused on sustaining growth, expanding margins, and delivering double-digit adjusted EPS growth.

Boston Scientific surpasses Q1 expectations, eyes growth through Farapulse

Boston Scientific's Q1 '23 earnings call showcased strong performance, with exceeding revenue expectations and solid organic sales growth. The company's strategic focus on high-growth M&A, resolving supply constraints for Farapulse, and capital allocation priorities position it well for future growth. Challenges include potential earnings dilutive deals and addressing free cash flow conversion challenges.

Boston Scientific surpasses Q2 expectations, eyes margin expansion and innovation

Boston Scientific delivered a strong Q2 '23 performance, exceeding expectations with robust sales growth and improved adjusted EPS, driven by strong performance across key regions and business segments.
While facing challenges such as inflation impact and market dynamics, the company remains focused on opportunities for margin expansion, product innovation, and strategic acquisitions to drive future growth.
With a positive outlook for the coronary business, upcoming product launches, and a commitment to operational excellence, Boston Scientific aims to maintain its competitive edge and capitalize on market opportunities.
Anticipated results from trials, market potential for new products, and a focus on sustainable growth strategies position Boston Scientific for continued success and market leadership in the healthcare sector.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities ahead

Boston Scientific's Q3 2023 results exceeded expectations, with strong performance across regions and business units.
The company raised full-year guidance, expecting organic revenue growth of approximately 11% and adjusted EPS range of $1.99 to $2.02.
Challenges in the Neuromodulation business and cost impacts are being addressed for future improvement.
Opportunities lie in acquisitions, FDA approvals, and strategic commercial initiatives for growth and margin expansion.

Boston Scientific (BSX) exceeds Q4 expectations, eyes growth opportunities

Boston Scientific (BSX) reported impressive Q4 2023 results, exceeding sales and EPS guidance.
The company showcased strong regional growth, highlighted key products, and outlined solid 2024 outlook.
While facing challenges like delayed product launches and market disruptions, BSX remains focused on growth opportunities.
Strategic acquisitions and margin improvement initiatives position Boston Scientific for continued success in the future.

Boston Scientific beats Q1 expectations, eyes growth in key markets

Boston Scientific delivered strong Q1 results, exceeding expectations and showcasing growth across key regions and business units.
While facing challenges like inventory charges, the company is focused on leveraging opportunities in expanding product indications and enhancing capabilities.
With raised full-year guidance and a focus on innovation and market expansion, Boston Scientific is poised for continued growth and success in 2024.

Boston Scientific (BSX) reports stellar Q2 results and eyes sustained growth

Boston Scientific's Q2 2024 performance exceeded expectations, showcasing strong financial results and regional sales growth across key markets.
The company's strategic strengths lie in diversified business units, innovative products like FARAPULSE, and strategic acquisitions like Silk Road Medical.
While challenges exist in adoption metrics and margin expansion, BSX's focus on reinvestment and growth opportunities position it well for sustained success.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities in Asia

Boston Scientific's Q3 performance exceeded expectations, driven by strong sales growth and increased adjusted EPS.
The company's focus on innovation and strategic investments in key business units like Cardiology and Neuromodulation bode well for future growth.
Despite challenges in China and the need to deliver on growth targets, Boston Scientific remains confident in its ability to sustain top-tier financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

LOS ANGELES--(BUSINESS WIRE)---- $BSX #CLASSACTION--Glancy Prongay & Murray LLP, Leading Securities Fraud Law Firm, Announces Investigation of Boston Scientific Corporation (BSX) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Boston Scientific Corporation (BSX) on Behalf of Investors

Addressing the elephant in the room - recent setbacks in TAVR. BSX has a premium Medical Devices portfolio that is likely to continue to grow above market in the medium term.

Boston Scientific - Looking Past The TAVR Setbacks

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 to November 16, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws. To join the Boston Scientific class action, go to http://www.rosenlegal.com/cases-register-2002.html or ca

ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Boston Scientific Corporation – BSX

Boston Scientific's (BSX) WaveWriter Alpha portfolio of SCS Systems aims to widen the therapy options available for managing chronic pain.

Boston Scientific's (BSX) SCS Systems Receives FDA's Nod

NEW YORK, Dec. 5, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the...

Pomerantz Law Firm Announces the Filing of a Class Action against Boston Scientific Corporation and Certain Officers - BSX

Amgen

Biogen

Biotech stocks are vulnerable to headlines, but these three have too much potential to ignore. Own them for a swing trade into 2021.

3 Under-Loved Biotech Stocks to Buy for Profits Into 2021

BTG's core Interventional Medicines business now is expected to exceed Boston Scientific's (BSX) original goal of $175 million in synergies.

Boston Scientific (BSX) to Divest BTG's Non-MedTech Arm

Boston Scientific Corp. said Tuesday it is selling its BTG Specialty Pharmaceuticals business to Stark International Lux S.A.R.L. and SERB SAS, both affiliates of specialty pharma group SERB, for $800 million in cash.

Boston Scientific sells BTG specialty pharma business to SERB affiliates for $800 million in cash

MARLBOROUGH, Mass., Dec. 1, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European specialty pharmaceutical group, to sell its BTG...

Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?

Why Is Boston Scientific (BSX) Down 1.5% Since Last Earnings Report?

NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX).   Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX

Here is an interesting fact. While most stocks have been climbing, Boston Scientific's stock is doing something different.

Boston Scientific's Stock Down 10%, What Comes Next?

MARLBOROUGH, Mass., Nov. 23, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1. Mike Mahoney, chairman and chief executive officer, and Susie Lisa, vice president, Investor Relations will...

Boston Scientific to Participate in Evercore ISI 2020 Healthcare Conference

NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating potential claims against Boston Scientific Corporation (NYSE: BSX) ("BSX" or the "Company") for violations of the federal securities laws. BSX's Lotus Edge is a transcatheter...

Investor Alert: Kaplan Fox Continues To Investigate Boston Scientific Corporation (BSX)

Despite a 47% rise since the March lows, at the current price of around $38 per share we believe Boston Scientific stock, has more room for growth in the near term. BSX stock has rallied from $26 to $38 off the recent bottom compared to the S&P which moved 60% over the same period, with the.

New Product Launches And Attractive Valuation To Drive Boston Scientific Stock Higher

Boston Scientific Corp. said Tuesday it has launched a voluntary recall of unused stock of its LOTUS Edge Aortic Valve System due to "complexities" relating to the product delivery system. "The voluntary recall is related solely to the delivery system, as the valve continues to achieve positive and clinically effective performance post-implant,' the company said in a statement.

Boston Scientific to voluntarily recall LOTUS Edge aortic valve system due to snag with delivery system

Boston Scientific (BSX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Boston Scientific (BSX) in Focus: Stock Moves 7% Higher

Boeing

Stocks are likely to consolidate or trend slightly higher.

Stocks This Week: Buy Boston Scientific And Sell Short Boeing

MARLBOROUGH, Mass., Nov. 5, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On November 12, 2020, Meghan Scanlon, senior vice president and president, Urology and Pelvic Health, and Susie Lisa, vice president,...

Boston Scientific Announces November 2020 Conference Schedule

MARLBOROUGH, Mass., Nov. 2, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the Ranger™ Drug-Coated Balloon, developed for the treatment of patients with peripheral artery disease (PAD) in the superficial...

Boston Scientific Receives FDA Approval for the Ranger™ Drug-Coated Balloon

MARLBOROUGH, Mass., Oct. 29, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device within a broad population of patients with...

Boston Scientific Initiates Trial to Evaluate WATCHMAN FLX™ Left Atrial Appendage Closure Device as First-Line Treatment for People at Risk of Stroke

Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q3 2020 Results - Earnings Call Transcript

Boston Scientific's (BSX) Q3 earnings and revenues decline year over year but improve sequentially.

Boston Scientific (BSX) Q3 Earnings Top, Margins Decline

MARLBOROUGH, Mass., Oct. 28, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.659 billion during the third quarter of 2020. This represents a decline of (1.8) percent on a reported basis, (2.5) percent on an operational1 basis and (5.7) percent on an...

Boston Scientific Announces Results For Third Quarter 2020

Boston Scientific Corp. posted a better-than-expected third-quarter adjusted profit and sales that topped estimates. The Marlborough, Mass.

News for Boston Scientific Stock (BSX)